+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Levodopa"

From
From
From
From
Parkinson's Disease: Epidemiology Forecast to 2033 - Product Thumbnail Image

Parkinson's Disease: Epidemiology Forecast to 2033

  • Report
  • November 2024
  • 39 Pages
  • Global
From
From
Transdermal CNS Therapeutics to 2028 - Product Thumbnail Image

Transdermal CNS Therapeutics to 2028

  • Report
  • July 2023
  • 115 Pages
  • Global
From
From
ABBV-951 Market Size, Forecast, and Market Insight - 2032 - Product Thumbnail Image

ABBV-951 Market Size, Forecast, and Market Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
ONGENTYS Market Size, Forecast, and Market Insight - 2032 - Product Thumbnail Image

ONGENTYS Market Size, Forecast, and Market Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
NOURIANZ Market Size, Forecast, and Market Insight - 2032 - Product Thumbnail Image

NOURIANZ Market Size, Forecast, and Market Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
INBRIJA Market Size, Forecast, and Market Insight - 2032 - Product Thumbnail Image

INBRIJA Market Size, Forecast, and Market Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
CVN-424 Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

CVN-424 Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
IPX203 Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

IPX203 Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
From
From
Levodopa-Induced Dyskinesia (LID) - Pipeline Insight, 2024 - Product Thumbnail Image

Levodopa-Induced Dyskinesia (LID) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Parkinson's disease - Pipeline Insight, 2024 - Product Thumbnail Image

Parkinson's disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 230 Pages
  • Global
From
Dyskinesia - Pipeline Insight, 2024 - Product Thumbnail Image

Dyskinesia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Loading Indicator

Levodopa is a drug used to treat Parkinson's disease, a neurological disorder that affects movement. It is a dopamine precursor, meaning it is converted into dopamine in the brain, which helps to reduce the symptoms of Parkinson's. Levodopa is usually taken in combination with other drugs, such as carbidopa, to increase its effectiveness. It is one of the most commonly prescribed drugs for Parkinson's, and is often the first line of treatment. Levodopa is a part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological disorders. The CNS drug market is highly competitive, with many different companies offering various treatments. Some of the companies in the Levodopa market include Merck, Novartis, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more